US16385C1045 - ADR
CHEMOMAB THERAPEUTICS LTD
NASDAQ:CMMB (5/10/2024, 7:00:01 PM)
After market: 0.84 +0 (+0.12%)0.839
+0.03 (+3.58%)
Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
CHEMOMAB THERAPEUTICS LTD
Kiryat Atidim, Building 7
TEL AVIV-YAFO 02139
CEO: Neil Cohen
Employees: 37
Website: https://www.chemomab.com/
Chemomab Therapeutics just reported results for the first quarter of 2024.
Chemomab reported on major progress in Q1 2024, including that it is on track to report Phase 2 PSC topline data at midyear 2024...
Chemomab CEO Adi Mor will present at the Aegis Virtual Conference on May 7 at 9:00am ET...
Here you can normally see the latest stock twits on CMMB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: